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Abstract
Background: Surfactant protein D (SP-D), an innate immune molecule, plays an important protective
role during airway inflammation. Deficiency of this molecule induces emphysematous changes in murine
lungs, but its significance in human COPD remains unclear.
Methods: We collected bronchoalveolar lavage fluid from 20 subjects with varying degrees of COPD (8
former smokers and 12 current smokers) and 15 asymptomatic healthy control subjects (5 never smokers,
3 remote former smokers, and 7 current smokers). All subjects underwent a complete medical history
and pulmonary function testing. SP-D was measured by Enzyme-Linked ImmunoSorbent Assay. Statistical
analysis was performed using nonparametric methods and multivariable linear regression for control of
confounding. The effect of corticosteroid treatment on SP-D synthesis was studied in vitro using an
established model of isolated type II alveolar epithelial cell culture.
Results: Among former smokers, those with COPD had significantly lower SP-D levels than healthy
subjects (median 502 and 1067 ng/mL, respectively, p = 0.01). In a multivariable linear regression model
controlling for age, sex, race, and pack-years of tobacco, COPD was independently associated with lower
SP-D levels (model coefficient -539, p = 0.04) and inhaled corticosteroid use was independently associated
with higher SP-D levels (398, p = 0.046). To support the hypothesis that corticosteroids increase SP-D
production we used type II alveolar epithelial cells isolated from adult rat lungs. These cells responded to
dexamethasone treatment by a significant increase of SP-D mRNA (p = 0.041) and protein (p = 0.037)
production after 4 days of culture.
Conclusion:  Among former smokers, COPD is associated with lower levels of SP-D and inhaled
corticosteroid use is associated with higher levels of SP-D in the lung. Dexamethasone induced SP-D
mRNA and protein expression in isolated epithelial cells in vitro. Given the importance of this molecule as
a modulator of innate immunity and inflammation in the lung, low levels may play a role in the pathogenesis
and/or progression of COPD. Further, we speculate that inhaled steroids may induce SP-D expression and
that this mechanism may contribute to their beneficial effects in COPD. Larger, prospective studies are
warranted to further elucidate the role of surfactant protein D in modulating pulmonary inflammation and
COPD pathogenesis.
Published: 28 January 2008
Respiratory Research 2008, 9:13 doi:10.1186/1465-9921-9-13
Received: 6 August 2007
Accepted: 28 January 2008
This article is available from: http://respiratory-research.com/content/9/1/13
© 2008 Sims et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
Page 2 of 9
(page number not for citation purposes)
Background
Chronic obstructive pulmonary disease (COPD) is charac-
terized, in part, by an abnormal inflammatory response of
the lung to noxious particles or gases [1], chiefly cigarette
smoke. Innate immunity is the vanguard of this multifac-
torial inflammatory response to cigarette smoke-induced
lung injury and may play an important role in COPD
pathogenesis. Despite a wealth of evidence suggesting that
surfactant protein D (SP-D) modulates innate immunity
in the lung, little is known about its role in human COPD.
Surfactant protein D (SP-D), together with surfactant pro-
tein A and mannose binding lectin, is a member of the
innate immune "collectin" family of structurally related
Ca2+ dependent lectins that share col lagen-like N-terminal
tails and globular lectin heads containing C-type carbohy-
drate recognition domains. Produced in alveolar type-II
cells and Clara cells, SP-D is a 43-kD monomer that forms
a higher order quaternary structure (usually a dodecamer
assembled from 4 homotrimers). SP-D binds to and
enhances clearance of a wide variety of pathogens [2-9],
promotes phagocytosis of apoptotic cells [10,11] and
inhibits pro-inflammatory cytokine release by effector
cells [6,12-14]. SP-D deficient mice display an abnormal
pulmonary phenotype characterized by activated alveolar
macrophages, increased levels of matrix metalloproteases
and emphysematous changes in the lung parenchyma
[15-17]. We and others have previously demonstrated that
these mice are more susceptible to lung injury from a vari-
ety of insults including bleomycin, ozone challenge, aller-
gic sensitization and viral, bacterial or pneumocystis
infection [13,14,16-20]. Because of the immunoprotec-
tive properties of SP-D, constitutive expression in the
proximal and distal airspaces appears essential in order to
maintain an immunologically hyporeactive tissue milieu
under normal (non-infectious) conditions.
The mechanisms that regulate expression and function of
this immunoprotective molecule are unknown. Previous
studies have found decreased levels of SP-D in the lung
[21,22] in association with cigarette smoking, but these
studies have not controlled for the potential confounding
effects of COPD. We hypothesized that chronic cigarette
smoking and COPD would each be independently associ-
ated with lower SP-D levels in the lung. In order to deter-
mine the association between pulmonary SP-D levels,
cigarette smoke exposure, and COPD, we conducted a
cross-sectional study of healthy nonsmokers, healthy
smokers, and current or former smokers with varying
degrees of COPD.
Methods
Human subjects
To study the role of SP-D in COPD, we recruited 20 sub-
jects with varying degrees of COPD (8 former smokers
and 12 current smokers) and 15 asymptomatic healthy
control subjects (5 never smokers, 3 remote former smok-
ers, and 7 current smokers), utilizing direct advertising in
the Philadelphia area. Volunteers deemed eligible after a
preliminary phone screen were scheduled for a screening
visit, during which a detailed medical history, tobacco his-
tory, medication history, and physical examination were
performed. Smoking status was confirmed by urine coti-
nine levels in all subjects. All subjects underwent spirom-
etry, lung volume assessment by plethysmography, and
measurement of the diffusing capacity for carbon monox-
ide. To qualify for the healthy non-smoker cohort, sub-
jects were required to be asymptomatic non-smokers with
a lifetime tobacco exposure of <10 pack years and no
tobacco in the last year. In addition, they were required to
demonstrate normal pulmonary function at screening.
Healthy smokers were required to be current, asympto-
matic smokers with a lifetime tobacco exposure of >10
pack years and normal pulmonary function at screening.
COPD subjects were required to have a lifetime tobacco
exposure of >10 pack years and to demonstrate incom-
pletely reversible airflow obstruction with a post-bron-
chodilator forced expiratory volume in one second (FEV1)
<80% predicted on screening spirometry. Disease severity
was established using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) classification [1].
Exclusion criteria included a history of asthma or alpha-1
antitrypsin deficiency, significant medical disease other
than COPD (benign conditions such as well-controlled
hypertension on minimal medication were allowed),
infection in the 3 weeks prior to screening, hospital
admission in the 3 months prior to screening, and prior
lung resection. Informed consent was obtained from all
subjects and the study protocol was approved by the Insti-
tutional Review Board of the University of Pennsylvania.
All included subjects underwent bronchoscopy one or
more times during the study. At each bronchoscopy, bron-
choalveolar lavage fluid (BALF) was collected by sequen-
tial instillation of three 50 mL aliquots of sterile saline
into a subsegmental bronchus followed by gentle syringe
suction. BALF was centrifuged at 1100 rpm for 10 minutes
and the cell-free supernatant was separated from the cell
pellet and preserved with a protease inhibitor tablet
(Roche Diagnostics, from Fisher Scientific, NC9225286)
before freezing for subsequent batched analysis.
Of the 35 subjects included in this study, 9 underwent
only one bronchoscopy, 22 underwent 2 separate bron-
choscopies (each with a separate BALF sample), and 4
underwent 3 bronchoscopies, depending on their partici-
pation in prior observational bronchoscopy studies at our
institution. Bronchoscopies for any given subject were
separated by a minimum of 3 months and no more than
9 months. For each subject, the average of all SP-D levelsRespiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
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obtained from the multiple BALF samples was used for all
analyses.
Human SP-D ELISA
Levels of SP-D and Clara cell protein (CCP-16, an anti-
inflammatory protein secreted by Clara cells) were meas-
ured in the cell free supernantant of BALF using an
Enzyme-Linked ImmunoSorbent Assay (ELISA) kit (Biov-
endor Inc, Brno, Czech Republic). ELISA was performed
according to the manufacturer's instructions. Total pro-
tein was assessed by standard Bradford assay. Given that
the ELISA measures absolute SP-D or CCP-16 concentra-
tions we are presenting the levels without normalization
for total protein content of the BAL. SP-D levels normal-
ized to the optical density obtained for protein measure-
ments did not significantly alter the results (data not
shown).
Alveolar Type II Cell Culture
Cells were isolated from adult rat lungs digested by colla-
genase I and collagenase IA (Sigma, St. Louis, MO) as pre-
viously described ([13,23,24]). Briefly, non adherent cells
were plated in 35 mm plastic culture dishes (2–2.5 × 106
cells/ml) in Waymouth's MB 752/1 Medium (Invitrogen,
Carlsbad, CA) with 10% fetal bovine serum and incubated
at 37°C, 5% CO2 overnight (day 0). (Approximately 40–
60% of all the cells plated were type II cells. This propor-
tion remained constant throughout the 4-day culture
period.) 24 hours later (day 1) cells were washed and fur-
ther incubated in serum-free Waymouth's medium with 8-
Br-cAMP (100 μM) and isobutylmethylxanthine (100
μM) with or without dexamethasone (10 nM) from Sigma
Chemical Co. (St. Louis, MO)] for an additional 3 days.
Cells were re-fed with fresh medium on day 3 and were
harvested on day 0, and day 4. Three individual experi-
ments were performed, each using duplicate cultures.
Western Blot and Northern Blot Analysis
To detect intracellular surfactant proteins, the cell pellet
was sonicated and the supernatant was concentrated by
evaporation. Western blot analysis was performed as pre-
viously described [25]. Membranes were incubated with
rabbit polyclonal anti-SP-D (1:10,000) or with rabbit pol-
yclonal anti-SP-A (1:7,500).
The 386-nucleotide rat cDNA probe for SP-D was newly
prepared using Reverse Transcription-Polymerase Chain
Reaction (RT-PCR) and the Retroscript Kit (Ambion, Aus-
tin, TX). Total RNA was isolated from type II cells by RNe-
asy kit (Qiagen, Valencia, CA) and Northern blot analysis
was performed as previously described [25].
Statistical analysis
In univariate analysis, SP-D levels were tested for associa-
tion with age, sex, race, disease status, smoking status,
total smoke exposure in pack-years, years since quit smok-
ing, and inhaled corticosteroid use. The Wilcoxon's rank-
sum test or Kruskal-Wallis test were used for categorical
variables with two or more than two levels, respectively,
and the Spearman test for correlation was used for contin-
uous variables. The association between disease status and
SP-D level in BALF was stratified by smoking status to con-
trol for possible confounding. Among former smokers,
SP-D levels approximated a normal distribution; as a
result, multivariable linear regression was used to test
whether the association between disease status and SP-D
levels within this group was independent of the effect of
other measured variables. Covariates were considered
confounders if they altered the association between dis-
ease and SP-D levels by 15% or more.
Further analyses included a non-parametric test for trend
[26] for SP-D levels among subjects categorized by the com-
bination of smoking and disease status, and a linear regres-
sion for SP-D levels among all subjects with smoking status
included as a categorical covariate rather than as a restrict-
ing factor. Bootstrap resampling was conducted to assess
the stability of our observed associations among 1000
repeated random samples of our dataset, using the "boot-
strap" command in STATA. This method creates numerous
datasets of equal size by random sampling of observations
in the original dataset with replacement and then recur-
sively conducts the specified statistical test on each new ran-
dom sample. Confidence intervals were then identified by
the percentile method (i.e. selecting the 2.5 and 97.5 per-
centile of the distribution of observed coefficients). Lastly,
one-way analysis of variance was used to calculate the
within-subject variability in SP-D level for subjects with
multiple samples available. All analyses were conducted
using STATA v.8 (StataCorp LP, College Station, TX).
Results
Patient characteristics
We recruited 20 subjects with varying degrees of COPD (8
former smokers and 12 current smokers) and 15 asympto-
matic healthy control subjects (5 never smokers, 3 remote
former smokers, and 7 current smokers). Subject character-
istics by disease status are listed in Table 1. Among subjects
with COPD, 9 were classified by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria as
GOLD 2 in severity, 8 were classified as GOLD 3, and 3
were classified as GOLD 4. Although GOLD 4 subjects had
lower SP-D levels than GOLD 2 and 3 subjects (median SP-
D levels 201 ng/mL for GOLD 4 and 461 ng/mL for GOLD
2 and 3), this difference did not reach statistical signifi-
cance (p = 0.37). As a result, all GOLD stages were pooled
together for further analyses. Healthy control subjects were
significantly younger than COPD subjects (median ages 51
and 59, respectively, p = 0.02). Although not statistically
significant, there were also differences in both gender andRespiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
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race between healthy controls and COPD subjects. There-
fore, we adjusted for each of these differences in the pri-
mary analysis. As shown in Table 1, lung function
parameters were lower while tobacco exposure was greater
among those with COPD relative to healthy controls.
Previously published studies on BALF SP-D levels from a
wide range of laboratories have shown only single sample
measurements. To investigate the variability in individual
BALF SP-D levels over time, we compared SP-D levels in
repeated BALF samples from subjects who underwent
multiple bronchoscopies as described in the Methods.
One-way analysis of variance revealed marked within-
subject variability over time (standard deviation 215 ng/
ml) in BALF SP-D levels from repeat samples obtained
within 3–9 months. This value was nevertheless lower
than the between-subject variability (standard deviation
306 ng/ml). To attain the most representative measure for
further analyses we used the average of SP-D levels
obtained from each subject.
Cigarette smoking was associated with reduced SP-D levels
Smoking status had a substantial impact on SP-D levels,
with former smokers having levels intermediate between
never smokers and current smokers (median SP-D levels
1078 ng/mL, 724 ng/mL, and 363 ng/mL for never,
former, and current smokers, respectively, p = 0.04 for the
difference between former and never smokers, p = 0.004
for the difference between current and never smokers).
Importantly, all former smokers in this cohort had quit a
minimum of 1.5 years prior to bronchoscopy, eliminating
the possibility that the lower levels in former smokers
were due to bias from recent cessation.
COPD was independently associated with reduced SP-D 
levels
Overall, subjects with COPD had lower SP-D levels in
their BALF compared with healthy subjects (median SP-D
levels 449 ng/mL and 714 ng/mL, respectively, p = 0.03).
In order to determine if the effect of disease status was
independent of the effect of smoking status, we stratified
subjects by smoking status and re-examined the effect of
disease status among former smokers and current smok-
ers, separately. Among current smokers, those with COPD
had only marginally lower SP-D levels in their BALF rela-
tive to healthy smoking controls, but this difference was
not statistically significant (p = 0.45). However, among
former smokers, COPD subjects had significantly lower
Table 1: Subject characteristics by disease status*
Healthy (n = 15) COPD (n = 20) p value
Age, years 51 (47 – 60) 59 (54 – 61) 0.02
Sex, n (%)
Male: 9 (60%) 8 (40%) 0.24
Female: 6 (40%) 12 (60%)
Race, n (%)
African-American: 8 (53%) 6 (30%) 0.12
White: 6 (40%) 14 (70%)
Asian: 1 (7%) 0
Smoking status, n (%)
Never: 5 (33%) 0 0.03
Fomer: 3 (20%) 8 (40%)
Current: 7 (47%) 12 (60%)
Tobacco exposure, pack years 12.5 (0 – 30) 53.3 (43 – 74.3) <0.0001
Inhaled corticosteroid (ICS) use, n (%) 0 (0%) 11 (55%) 0.001
ICS use by smoking status, n (%)
Never: 0 (0%) 0 (0%) N/A
Fomer: 0 (0%) 4 (50%) 0.24
Current: 0 (0%) 7 (58%) 0.02
FEV1, %predicted 102% (96% – 109%) 48% (34% – 65%) <0.0001
FVC, %predicted 100% (88% – 108%) 80% (68% – 94%) 0.001
FEV1/FVC, %predicted 100% (98% – 106%) 59.5% (48.5% – 74.5%) <0.0001
TLC, %predicted 105% (90% – 111%) 117% (106% – 127%) 0.007
RV, %predicted 98% (88% – 109%) 165.5% (145% – 199.5%) <0.0001
DLCO, % predicted 99% (84% – 117%) 61.5% (48.5% – 68%) <0.0001
SP-D, ng/mL 714 (445 – 1078) 449 (310 – 664) 0.03
SP-D by smoking status, ng/mL
Never: 1078 (1065 – 1239) N/A N/A
Fomer: 1067 (861 – 1110) 502 (449 – 765) 0.01
Current: 445 (334 – 704) 334 (290 – 533) 0.45
*All values expressed as median (IQR) unless otherwise specifiedRespiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
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SP-D levels in their BALF relative to healthy controls (p =
0.01), suggesting that COPD is associated with lower lev-
els of SP-D in the lung independent of smoking status
(Figure 1).
Inhaled corticosteroid use was independently associated 
with SP-D levels
Since previous studies from our laboratory suggested that
corticosteroids may increase SP-D expression [13,24], we
examined inhaled corticosteroid (ICS) use as a potential
confounder in our study. In univariate analysis, among
former smokers with COPD, ICS use was associated with
a trend toward higher SP-D levels in comparison to those
not using ICS (median SP-D levels 765 ng/mL and 463
ng/mL, respectively, p = 0.15). ICS use was not associated
with increased SP-D levels among current smokers with
COPD.
Next, we used multivariable linear regression to test
whether the association between disease and SP-D levels
among former smokers was independent of ICS use. Inter-
estingly, when ICS use was included as a categorical vari-
able in the model with disease status, both maintained an
independent association with SP-D levels. Indeed the
magnitude of association between disease status and SP-D
levels increased. Even when age, sex, race, and tobacco
exposure in pack-years were sequentially forced into the
model, both disease and ICS use retained independent
associations with SP-D levels (Table 2), eliminating the
possibility that our observed associations were due to con-
founding by these factors.
In order to further examine the stability of our findings,
we employed bootstrap resampling, creating 1000 repli-
cates for the model including disease status and ICS use.
This analysis confirmed that the associations observed for
disease status and use of inhaled corticosteroids were
robust (model coefficients [95% CI] were -600 [-826, 0.0]
and 290 [13, 516], respectively).
Effects of dexamethasone on type II alveolar epithelial cell 
SP-D levels
To investigate whether corticosteroids would be capable
of directly affecting SP-D synthesis we isolated type II alve-
olar epithelial cells from adult rat lungs. Cells were cul-
tured for 4 days in the presence or absence of
dexamethasone (10 ng/ml). Figure 2 demonstrates that
dexamethasone induced a significant increase in SP-D
expression (p = 0.037). This increase was commensurate
with a raise in SP-D mRNA in these cells (p = 0.041). The
effects of dexamethasone were specific because protein
expression of the other lung collectin, SP-A did not
increase in the presence of this glucocorticoid. These data
suggest that dexamethasone is capable of directly enhanc-
ing SP-D production by type II alveolar epithelial cells.
COPD selectively affected SP-D levels in the BALF
To exclude the possibility that lower levels of SP-D among
former smokers with COPD were due to a non-specific
loss of pulmonary proteins through epithelial destruc-
tion, we re-examined our multivariable model for former
smokers using SP-D levels normalized to total protein
SP-D levels in BALF according to smoking and disease status Figure 1
SP-D levels in BALF according to smoking and dis-
ease status. P value shown on the graph is for the overall 
trend in SP-D levels by a nonparametric test for trend. * p = 
0.01 for the difference between healthy former smokers and 
former smokers with COPD. ** p = 0.45 for the difference 
between healthy current smokers and current smokers with 
COPD.
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Table 2: Multivariable analysis among former smokers
Variables Included Model Coefficient p value
B0 1342 0.07
COPD (vs. Healthy) -539 0.04
ICS use 398 0.046
Age -10 0.34
Sex 110 0.53
Race (African-American vs. White) 216 0.26
Tobacco (pack-years) 2.0 0.52Respiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
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concentration. This model yielded comparable results for
the effect of disease on SP-D levels (model coefficient
[95% CI] -1162 [-2078, -257], p = 0.02) even after con-
trolling for age, race, pack-years of tobacco use, and ICS
use (only when sex was included in the model did the
coefficient rise to -981 with a p value of 0.079). In addi-
tion, we analyzed Clara cell protein (CCP-16, a protein
produced by Clara cells) in the BALF in comparison with
SP-D levels. Although former smokers with COPD did
have a small but statistically significant reduction in CCP-
16 levels compared to healthy former smokers (median
CCP-16 levels 9.2 mcg/mL vs. 22.6 mcg/mL, respectively,
p = 0.04), this difference disappeared with control for any
potential confounders, including age, race, sex, pack-years
of tobacco use, or ICS use. This sharply contrasted with
the effect of disease on levels of SP-D, which remained sta-
tistically significant despite inclusion of all of these con-
founders, simultaneously. Thus, the reduced SP-D levels
in association with COPD appear to be a specific phe-
nomenon rather than simply reflecting an overall decrease
in pulmonary proteins due to loss of airway epithelium.
To further investigate the relationship between smoking
and COPD with regard to SP-D levels, we subdivided our
cohort into 5 groups consisting of healthy never smokers (n
= 5), healthy former smokers (n = 3), former smokers with
COPD (n = 8), healthy current smokers (n = 7), and current
smokers with COPD (n = 12). We then analyzed pulmo-
nary SP-D levels by this categorization and found that there
was a very strong pattern of progressive decline in SP-D lev-
els as determined by a non-parametric test for trend (p <
0.001; Figure 1). These data support our observation that
both smoking status and COPD have independent effects
on SP-D levels. This analysis also highlighted the effect of
smoking among healthy subjects: healthy current smokers
had lower levels of SP-D in the BALF relative to healthy
never smokers (median SP-D levels 445 ng/mL and 1078
ng/mL, respectively, p = 0.007) but there was no difference
in SP-D levels between healthy former smokers and healthy
never smokers (median SP-D levels 1067 ng/mL and 1078
ng/mL, respectively, p = 0.65).
In order to determine if the association between COPD
and SP-D levels would remain despite including all smok-
ing strata, we also repeated our multivariable linear regres-
sion on the entire cohort (Table 3), including smoking
status as a categorical covariate. Due to probable colline-
arity, we were unable to develop a stable model including
an interaction term between disease status and smoking
status. When both variables were included in the model as
main effects without an interaction, the association of
smoking status with SP-D levels was stronger than that of
disease status with SP-D levels. When race was added to
the model with smoking status (omitting disease status),
the estimates of association for smoking strata were not
altered. However, African-American race was associated
with significantly higher SP-D levels compared to white
race.
Dexamethasone upregulates SP-D but not SP-A production  by type II cells in vitro Figure 2
Dexamethasone upregulates SP-D but not SP-A pro-
duction by type II cells in vitro. Cells were isolated from 
lungs of adult rats and cultured in Waymouth's medium with 
10% FBS, with 8-Br-cAMP (100 μM) and isobutylmethylxan-
thine (100 μM) with or without dexamethasone (10 nM). 
Cell lysates were prepared from freshly isolated cells and at 
the end of a 4-day culture period (A): SP-A and SP-D produc-
tion was analyzed by Western blot. (B): Results are 
expressed as % of the "day 0" value. *p = 0.037 (n = 3) (C): 
Northern blot analysis of SP-D and SP-A mRNA expression 
was performed on total RNA (10 μg) extracted from type II 
cells as described. SP-D and SP-A cDNA probes labeled with 
[α32P] dCTP were hybridized to mRNAs on nitrocellulose 
membranes. (D): Intensity was quantified by densitometric 
scanning and the hybridization signals were normalized to 
28S rRNA probe labeled with [γ32P] ATP. mRNA content is 
expressed as % of the "day 0" value. *p < 0.041 Mean ± SEM 
was calculated after deriving the average of the results from 
three independent experiments.
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Table 3: Multivariable analysis among all subjects
Variables Included Model Coefficient p value
B0
Smoking status (former vs. never) 970 < 0.001
(current vs. never) -356 0.02
-628 < 0.001
Race (African-American vs. White) 248 0.01
(Asian vs. White) 103 0.71Respiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
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Discussion
The relationship between smoking and innate lung
immunity remains poorly defined. In this study, we dem-
onstrate a significant relationship between COPD and
lower levels of pulmonary SP-D that is independent of
current cigarette smoke exposure and controlled for mul-
tiple potential confounders. In addition, for the first time,
controlled data indicates an association between the use
of inhaled corticosteroids and increased levels of pulmo-
nary SP-D. Given the importance of SP-D as a regulator of
innate immunity and inflammation in the lung [13-15],
we speculate that depletion and/or dysfunction of this
protective lung collectin may contribute to disease patho-
genesis and progression. Our intriguing observations
among former smokers suggest that SP-D expression may
be a novel biomarker reflecting the presence of disease
and steroid effects, and may also suggest a potential role
for this molecule in COPD pathogenesis.
The association between COPD and SP-D levels was not
statistically significant among current smokers or when
smoking status was included as a categorical covariate for
the entire cohort. We postulate that the acute effect of cur-
rent cigarette smoke exposure on pulmonary SP-D levels
overshadows the chronic effect of COPD, such that the
effect of disease was only detectable among former smok-
ers. Further studies with larger numbers of patients, and
thus greater statistical power, will be required to deter-
mine whether an effect of disease can be detected among
current smokers.
Similarly, subjects in our study with very severe COPD
(GOLD 4) had lower levels of SP-D compared with subjects
with GOLD stage 2 or 3 disease, but this difference was not
statistically significant. While we hypothesize that greater
disease severity is associated with lower SP-D levels, our
study was underpowered to detect this difference. Clearly,
further studies with larger numbers of subjects will be
required to ultimately prove or disprove this hypothesis.
In our study, no distinction was made between COPD sub-
jects fitting the emphysema phenotype and those fitting a
more chronic bronchitic phenotype. Although SP-D may
be differentially affected in these disparate phenotypes, any
such difference would likely bias our study toward the null
hypothesis; that is, such differences would increase the
overall variability in SP-D levels among COPD subjects and
thus increase the likelihood of failing to detect an associa-
tion. Thus, that this variability would cause a spurious dif-
ference (i.e. a type-I error) is unlikely. Similarly, although
definitive exclusion of asthma in clinical studies of COPD
subjects with symptomatic airflow obstruction is quite
challenging, the likelihood of asthma confounding our
results is low. We carefully excluded subjects with a history
of asthma, our COPD subjects were relatively old (median
age 59, minimum age 49) with a substantial tobacco expo-
sure history (median 53 pack-years, minimum 23 pack-
years) and incompletely reversible airflow obstruction.
It is possible that SP-D levels are lower in those with dis-
ease as a result of disease-related epithelial destruction
that depletes the Clara cells and Type-II alveolar cells
responsible for SP-D production. As such, SP-D could
simply be acting as a marker of parenchymal destruction
in COPD. Arguing against this is the fact that normalizing
SP-D levels to the optical density for protein measurement
did not substantially change the results of our multivaria-
ble model and that CCP-16 levels did not appear to be
altered by disease independent of confounding. These
results indicate that the ability to produce SP-D is unlikely
to be a simple reflection of the extent of emphysematous
changes in the distal air spaces.
Regardless of whether lower SP-D expression in COPD
subjects is due to parenchymal destruction, depletion of
this protective molecule may still have a substantial effect
on subsequent disease progression and susceptibility to
infection. In murine models, mice deficient in SP-D dis-
play a markedly abnormal phenotype with pulmonary
emphysema, accumulations of activated macrophages,
and increased levels of matrix metalloproteases
[15,20,27-29], all of which are characteristic of emphy-
sema in humans. These mice are more susceptible to lung
injury from a variety of insults including bleomycin,
ozone challenge, allergic sensitization and viral, bacterial
or pneumocystis infection [13,14,16-20]. Further, treat-
ment of SP-D deficient mice with a recombinant fragment
of SP-D has been demonstrated to reverse these patho-
logic changes [10,30], suggesting that SP-D is more than
just a marker of parenchymal destruction and appears to
play an important regulatory role in the lung. These data
suggest that SP-D modulates the immune response to pul-
monary infection and the inflammatory response to lung
injury. Thus, to the extent that these murine models are
reflective of human disease, it appears that relative defi-
ciency of this protective molecule may confer increased
susceptibility to infection and disease progression.
Interestingly, in our model including all 35 subjects, Afri-
can-American race was associated with higher SP-D levels
independent of smoking status. While possible explana-
tions such as differences in types of tobacco smoked or
other smoking-related behaviors are plausible, this effect
could potentially represent genetically regulated differ-
ences in expression. Indeed, in humans allelic variations
have been shown to be strongly associated with differ-
ences in SP-D serum levels [31]. Heidinger et al. reported
that a single SP-D gene haplotype had a highly significant
negative association with serum SP-D levels. In addition,
several single nucleotide polymorphisms in genes encod-Respiratory Research 2008, 9:13 http://respiratory-research.com/content/9/1/13
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ing surfactant proteins have been linked to COPD in a
Mexican population [32]. Whether genetic predisposition
to low levels of SP-D production would increase suscepti-
bility to develop COPD upon exposure to cigarette smoke,
however, needs further clarification. Importantly, our
observed association between COPD and lower SP-D lev-
els among former smokers remained significant despite
controlling for race in our multivariable analysis, exclud-
ing the possibility that racial differences in SP-D expres-
sion confounded our results.
Our multivariate analysis suggested that ICS use was inde-
pendently associated with higher SP-D levels in the lung of
former smokers with COPD. Corticosteroids have been
shown to induce expression of SP-D in the fetal lung tissue
of both rats [24,33-35] and humans [36-38]. Here we
investigated adult type II alveolar epithelial cells isolated
from rat lungs. We found that similarly to fetal cells, SP-D
synthesis depended on constitutive presence of dexameth-
asone. Indeed this glucocorticoid significantly enhanced
expression of both mRNA and protein for SP-D. Given that
there are several high potency inhaled steroids widely used
to treat COPD and that these steroids are deposited directly
on the epithelium, the site of SP-D production, it is reason-
able to suspect that these medications may have effects on
local SP-D gene expression. Given the high level of evolu-
tional conservation of the SP-D gene promoter sequence
between rats and humans, we speculate that inhaled corti-
costeroids induce expression of SP-D in the adult human
lung. Further, this mechanism may enhance the anti-
inflammatory effects of inhaled corticosteroids in COPD.
In summary, we have demonstrated for the first time an
association between decreased SP-D levels in the lung and
COPD that is independent of current cigarette smoke
exposure. We hypothesize that chronic exposure to ciga-
rette smoke reduces SP-D expression and that subsequent
relative deficiency of this protective molecule impairs
innate immunity and contributes to the pulmonary
inflammation characteristic of COPD. In this cross-sec-
tional study, we were unable to determine the temporal
association between lower SP-D levels and development
of disease, making causal inference tentative at best.
Larger studies with prospective follow-up are warranted to
determine whether our observations are reproducible and
predictive of subsequent clinical outcomes. Our study
emphasizes that the relationship between COPD, corti-
costeroid therapy, and the structure and function of pul-
monary SP-D merits further investigation.
Conclusion
Among former smokers, COPD is associated with lower
levels of SP-D and inhaled corticosteroid use is associated
with higher levels of SP-D in the lung. Given the impor-
tance of this molecule as a modulator of innate immunity
and inflammation in the lung, low levels may play a role
in the pathogenesis and/or progression of COPD. We
speculate that inhaled steroids may induce SP-D expres-
sion and that this mechanism could contribute to their
anti-inflammatory effects in COPD. Larger, prospective
studies are needed to further elucidate the role of sur-
factant protein D in modulating pulmonary inflamma-
tion and COPD pathogenesis.
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